AnaptysBio Inc Cash Flow-to-Debt Ratio
AnaptysBio Inc cash flow-to-debt ratio. AnaptysBio Inc (ANAB) has a Cash Flow-to-Debt Ratio of -0.08x as of March 2026, meaning its operating cash flow of $-25.92 Million could theoretically repay 0% of its total liabilities ($316.94 Million) in one year. Check earnings quality score of AnaptysBio Inc to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of AnaptysBio Inc (2013–2025)
Cash flow-to-debt ratio of AnaptysBio Inc from 2013 to 2025. Historical debt coverage capacity for AnaptysBio Inc across 13 annual periods. Check ANAB capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
AnaptysBio Inc Cash Flow-to-Debt Ratio by Year (2013–2025)
AnaptysBio Inc cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for AnaptysBio Inc. For the full cash flow conversion analysis, see how efficiently does AnaptysBio Inc generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.06x | $19.70 Million | $327.19 Million | ▲ +118.4% |
| 2024 | -0.33x | $-135.34 Million | $412.97 Million | ▲ +1.2% |
| 2023 | -0.33x | $-120.80 Million | $364.29 Million | ▼ -56.9% |
| 2022 | -0.21x | $-73.59 Million | $348.28 Million | ▼ -31.9% |
| 2021 | -0.16x | $-45.92 Million | $286.64 Million | ▲ +77.6% |
| 2020 | -0.71x | $-14.16 Million | $19.82 Million | ▲ +69.0% |
| 2019 | -2.30x | $-69.52 Million | $30.19 Million | ▼ -7.4% |
| 2018 | -2.14x | $-48.51 Million | $22.63 Million | ▼ -140.2% |
| 2017 | -0.89x | $-19.44 Million | $21.78 Million | ▼ -126.4% |
| 2016 | -0.39x | $-9.03 Million | $22.91 Million | ▲ +43.2% |
| 2015 | -0.69x | $-9.67 Million | $13.94 Million | ▼ -190.6% |
| 2014 | 0.77x | $14.60 Million | $19.07 Million | ▲ +149.8% |
| 2013 | -1.54x | $-5.80 Million | $3.77 Million | — |